175 related articles for article (PubMed ID: 33658640)
1. Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.
Gampala S; Shah F; Zhang C; Rhodes SD; Babb O; Grimard M; Wireman RS; Rad E; Calver B; Bai RY; Staedtke V; Hulsey EL; Saadatzadeh MR; Pollok KE; Tong Y; Smith AE; Clapp DW; Tee AR; Kelley MR; Fishel ML
Br J Cancer; 2021 Apr; 124(9):1566-1580. PubMed ID: 33658640
[TBL] [Abstract][Full Text] [Related]
2. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
[TBL] [Abstract][Full Text] [Related]
3. Galectin-1 inhibition induces cell apoptosis through dual suppression of CXCR4 and Ras pathways in human malignant peripheral nerve sheath tumors.
Shih TC; Fan Y; Kiss S; Li X; Deng XN; Liu R; Chen XJ; Carney R; Chen A; Ghosh PM; Lam KS
Neuro Oncol; 2019 Nov; 21(11):1389-1400. PubMed ID: 31127849
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth.
Yang K; Guo W; Ren T; Huang Y; Han Y; Zhang H; Zhang J
J Exp Clin Cancer Res; 2019 May; 38(1):185. PubMed ID: 31053152
[TBL] [Abstract][Full Text] [Related]
5. APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival.
Cardoso AA; Jiang Y; Luo M; Reed AM; Shahda S; He Y; Maitra A; Kelley MR; Fishel ML
PLoS One; 2012; 7(10):e47462. PubMed ID: 23094050
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co-culture models.
Caston RA; Shah F; Starcher CL; Wireman R; Babb O; Grimard M; McGeown J; Armstrong L; Tong Y; Pili R; Rupert J; Zimmers TA; Elmi AN; Pollok KE; Motea EA; Kelley MR; Fishel ML
J Cell Mol Med; 2021 Jan; 25(2):784-800. PubMed ID: 33274592
[TBL] [Abstract][Full Text] [Related]
7. Functional imaging of RAS pathway targeting in malignant peripheral nerve sheath tumor cells and xenografts.
Butler E; Schwettmann B; Geboers S; Hao G; Kim J; Nham K; Sun X; Laetsch TW; Xu L; Williams NS; Skapek SX
Pediatr Blood Cancer; 2020 Dec; 67(12):e28639. PubMed ID: 32975370
[TBL] [Abstract][Full Text] [Related]
8. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms.
Longo JF; Brosius SN; Black L; Worley SH; Wilson RC; Roth KA; Carroll SL
Cell Commun Signal; 2019 Jul; 17(1):74. PubMed ID: 31291965
[TBL] [Abstract][Full Text] [Related]
9. R-Ras subfamily proteins elicit distinct physiologic effects and phosphoproteome alterations in neurofibromin-null MPNST cells.
Weber SM; Brossier NM; Prechtl A; Barnes S; Wilson LS; Brosius SN; Longo JF; Carroll SL
Cell Commun Signal; 2021 Sep; 19(1):95. PubMed ID: 34530870
[TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer.
Fishel ML; Xia H; McGeown J; McIlwain DW; Elbanna M; Craft AA; Kaimakliotis HZ; Sandusky GE; Zhang C; Pili R; Kelley MR; Jerde TJ
Mol Cancer Ther; 2019 Nov; 18(11):1947-1960. PubMed ID: 31413178
[TBL] [Abstract][Full Text] [Related]
11. New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types.
Gampala S; Moon HR; Wireman R; Peil J; Kiran S; Mitchell DK; Brewster K; Mang H; Masters A; Bach C; Smith-Kinnamen W; Doud EH; Rai R; Mosley AL; Quinney SK; Clapp DW; Hamdouchi C; Wikel J; Zhang C; Han B; Georgiadis MM; Kelley MR; Fishel ML
Pharmacol Res; 2024 Mar; 201():107092. PubMed ID: 38311014
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?
Gaspard M; Lamant L; Tournier E; Valentin T; Rochaix P; Terrier P; Ranchere-Vince D; Coindre JM; Filleron T; Le Guellec S
Histopathology; 2018 Dec; 73(6):969-982. PubMed ID: 30137667
[TBL] [Abstract][Full Text] [Related]
13. Combined Targeting of AKT and mTOR Inhibits Proliferation of Human NF1-Associated Malignant Peripheral Nerve Sheath Tumour Cells In Vitro but not in a Xenograft Mouse Model In Vivo.
Schulte A; Ewald F; Spyra M; Smit DJ; Jiang W; Salamon J; Jücker M; Mautner VF
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102484
[TBL] [Abstract][Full Text] [Related]
14. Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth.
Fishel ML; Jiang Y; Rajeshkumar NV; Scandura G; Sinn AL; He Y; Shen C; Jones DR; Pollok KE; Ivan M; Maitra A; Kelley MR
Mol Cancer Ther; 2011 Sep; 10(9):1698-708. PubMed ID: 21700832
[TBL] [Abstract][Full Text] [Related]
15. Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.
Chang LS; Oblinger JL; Burns SS; Huang J; Anderson LW; Hollingshead MG; Shen R; Pan L; Agarwal G; Ren Y; Roberts RD; O'Keefe BR; Kinghorn AD; Collins JM
Mol Cancer Ther; 2020 Mar; 19(3):731-741. PubMed ID: 31848295
[TBL] [Abstract][Full Text] [Related]
16. The neurofibromatosis type 1 tumor suppressor controls cell growth by regulating signal transducer and activator of transcription-3 activity in vitro and in vivo.
Banerjee S; Byrd JN; Gianino SM; Harpstrite SE; Rodriguez FJ; Tuskan RG; Reilly KM; Piwnica-Worms DR; Gutmann DH
Cancer Res; 2010 Feb; 70(4):1356-66. PubMed ID: 20124472
[TBL] [Abstract][Full Text] [Related]
17. Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models.
Logsdon DP; Grimard M; Luo M; Shahda S; Jiang Y; Tong Y; Yu Z; Zyromski N; Schipani E; Carta F; Supuran CT; Korc M; Ivan M; Kelley MR; Fishel ML
Mol Cancer Ther; 2016 Nov; 15(11):2722-2732. PubMed ID: 27535970
[TBL] [Abstract][Full Text] [Related]
18. Ref-1/APE1 as a Transcriptional Regulator and Novel Therapeutic Target in Pediatric T-cell Leukemia.
Ding J; Fishel ML; Reed AM; McAdams E; Czader MB; Cardoso AA; Kelley MR
Mol Cancer Ther; 2017 Jul; 16(7):1401-1411. PubMed ID: 28446640
[TBL] [Abstract][Full Text] [Related]
19. Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: exploiting this novel finding as a potential target.
Gampala S; Shah F; Lu X; Moon HR; Babb O; Umesh Ganesh N; Sandusky G; Hulsey E; Armstrong L; Mosely AL; Han B; Ivan M; Yeh JJ; Kelley MR; Zhang C; Fishel ML
J Exp Clin Cancer Res; 2021 Aug; 40(1):251. PubMed ID: 34376225
[TBL] [Abstract][Full Text] [Related]
20. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
